Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $80.1 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Evkeeza, Libtayo, Inmazeb, Arcalyst, and Zaltrap. The biotechnology company is expected to announce its fiscal third-quarter earnings for 2026 before the market opens on Friday, Oct. 30.
Ahead of the event, analysts expect Regeneron Pharmaceuticals to report a profit of $13.58 per share on a diluted basis, up 41% from $9.63 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.